Mahmoud, A., Soliman, M., Moustafa, A. (2021). Evaluation of Monocyte Chemoattractant Protein 1(MCP-1) as a Predictor of Complications in Type 2 Diabetes Mellitus in Zagazig University Hospital. The Egyptian Journal of Hospital Medicine, 83(1), 995-1001. doi: 10.21608/ejhm.2021.160038
Amira A. Mahmoud; Mohamed Said Soliman; Azza Moustafa. "Evaluation of Monocyte Chemoattractant Protein 1(MCP-1) as a Predictor of Complications in Type 2 Diabetes Mellitus in Zagazig University Hospital". The Egyptian Journal of Hospital Medicine, 83, 1, 2021, 995-1001. doi: 10.21608/ejhm.2021.160038
Mahmoud, A., Soliman, M., Moustafa, A. (2021). 'Evaluation of Monocyte Chemoattractant Protein 1(MCP-1) as a Predictor of Complications in Type 2 Diabetes Mellitus in Zagazig University Hospital', The Egyptian Journal of Hospital Medicine, 83(1), pp. 995-1001. doi: 10.21608/ejhm.2021.160038
Mahmoud, A., Soliman, M., Moustafa, A. Evaluation of Monocyte Chemoattractant Protein 1(MCP-1) as a Predictor of Complications in Type 2 Diabetes Mellitus in Zagazig University Hospital. The Egyptian Journal of Hospital Medicine, 2021; 83(1): 995-1001. doi: 10.21608/ejhm.2021.160038
Evaluation of Monocyte Chemoattractant Protein 1(MCP-1) as a Predictor of Complications in Type 2 Diabetes Mellitus in Zagazig University Hospital
ABSTRACT Background: Monocyte chemoattractant protein-1 (MCP-1) is the first discovered and most extensively studied chemotactic cytokines (CC = chemokine). Many studies on its role in the etiologies of obesity- and diabetes-related diseases have been increased exponentially during the past two decades. MCP-1, a chemokine involved in monocyte chemotaxis can be consistently found at high levels in the patients with type 2 diabetes mellitus. MCP1 may be an early predictor of complications of diabetes. Objective: Assessment of the levels of MCP-1 and other biochemical markers in diabetic subjects compared to a healthy group, which in turn can be beneficial to clarify the correlations of MCP-1 levels in diabetes mellitus with other clinical and biochemical parameters. Patients and methods: Eighty-one participants including both male and female, of cross-matched ages ranging between 30 – 60 years old were included in this study. They were divided into three equal groups: group I (control group), group II (recently diagnosed T2DM) and group III (old diagnosed T2DM more than 10 years). Results: The highest level of MCP-1 was found in the old diagnosed diabetic group while the lowest level was found in the non-diabetic control group. The LSD statistical analysis showed there was significant difference between all groups of the study. Our results showed that serum MCP-1 was elevated in cases of the group 3 (old diagnosed diabetic patients) who were suffering from diabetic nephropathy (9/27), diabetic retinopathy (9/27) and the last 9/27 were suffering of neuropathy. Conclusion: The MCP-1 level is increased in type 2 Diabetic patients and significantly increased with the progression of diabetes complications as diabetic retinopathy, diabetic nephropathy and diabetic neuropathy.
View on SCiNiTO
Top